BioNTech’s (BNTX) “Outperform” Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of BioNTech (NASDAQ:BNTX) in a research report sent to investors on Monday morning, Marketbeat Ratings reports.

Several other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Canaccord Genuity Group raised their price objective on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft upped their target price on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, Bank of America upped their price objective on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Stock Performance

Shares of BioNTech stock opened at $117.20 on Monday. The firm has a 50 day simple moving average of $113.81 and a 200 day simple moving average of $98.77. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market cap of $28.10 billion, a P/E ratio of -56.68 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.73 earnings per share. Sell-side analysts predict that BioNTech will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Candriam S.C.A. lifted its holdings in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Fred Alger Management LLC acquired a new stake in BioNTech in the 3rd quarter valued at approximately $59,485,000. Baillie Gifford & Co. boosted its position in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after acquiring an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after acquiring an additional 7,340 shares in the last quarter. Finally, Discovery Capital Management LLC CT acquired a new stake in shares of BioNTech in the second quarter valued at approximately $2,467,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.